AN2 Therapeutics Inc (ANTX)
2.265
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
2.265
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Research and Development Expense (TTM): 57.54M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 57.54M |
| December 31, 2023 | 54.87M |
| September 30, 2023 | 48.70M |
| June 30, 2023 | 42.70M |
| March 31, 2023 | 35.86M |
| Date | Value |
|---|---|
| December 31, 2022 | 29.51M |
| September 30, 2022 | 26.57M |
| June 30, 2022 | 23.49M |
| March 31, 2022 | 20.89M |
| December 31, 2021 | 16.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
16.91M
Minimum
Dec 2021
57.54M
Maximum
Mar 2024
35.70M
Average
32.69M
Median
Research and Development Expense (TTM) Benchmarks
| Revance Therapeutics Inc | 70.63M |
| Viking Therapeutics Inc | 76.90M |
| VYNE Therapeutics Inc | 17.28M |
| Aquestive Therapeutics Inc | 15.49M |
| Humacyte Inc | 80.54M |